Connect with us

National

ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses – Business Wire

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine

Published

on

Article feature image

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations. The company presented the results in an oral presentation at the 28th Conference on Retroviruses and Opportunistic Infections (CROI) and published the positive findings of high binding affinity to the variants in preprint server, bioRxiv…

Click here to view the original article.